I will try to answer that. We have several pharmaceutical companies, of course, as you would expect, from the U.S. They are coming over to use the synchrotron. They are doing protein crystallography for drug development, and that's the end of our knowledge. They are not telling us any details. They are paying for the utilization—that means the commercial utilization is paid for—and they are stopping at one point. They are using it and they are not telling us which drugs they are developing.
On October 30th, 2012. See this statement in context.